［1］ Chen Z M, Jiang L X, Chen Y P, et al．Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial［J］．Lancet, 2005, 366(9497) : 1607-1621．
［2］ Buchanan M R, Brister S J. Individual variation in the effects of ASA on platelet functionimplications for the use of ASA clinically［J］. Can J Cardiol, 1995,11(3):221–227.
［3］ Gurbel P A, Bliden K P, Hiatt B L, et al .Clopidogrel for coronary stentingresponse variability, drug resistance, and the effect of pretreatment platelet reactivity［J］. Circulation, 2003,107(23)：2908–2913.
［4］ Lev E I, Patel R T, Maresh K J, et al．Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance［J］. J Am Coll Cardiol，2006，47(1):27-33.
［5］ Weber A A, Przytulski B, Schanz A, et al．Towards a definition of aspirin resistance: a typological approach［J］. Platelets，2002,13(1):37-40.
［6］ Szczeklik A,Musial J, Undas A, et al. Aspirin resistance. J Thromb Haemost,2005,3(8):1655-1662.
［7］ Gum P A, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease［J］. J Am Coll Cardiol，2003,41(6):961-965.
［8］ Müller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement［J］.Thromb Haemost，2003,89(5):783-787．
［9］ Gurbel P A，Bliden K P，Hiatt B L, et al．Clopidogrel for coronary stenting：response variability, drug resistance, and the effect of pretreatment platelet reactivity［J］.Circulation,2003,107(23):2908-2913．
［10］ Michelson A D. Platelet function testing in cardiovascular diseases［J］. Circulation，2004,110(19):e489–e493.
［11］ Feuring M, Schultz A, Losel R, et al. Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100［J］. Semin Thromb Hemost，2005，31(4):411-415.
［12］ Michelson A D. Methods for the measurement of platelet function［J］. Am J Cardiol， 2009, 103(3 Suppl):20A-26A.
［13］ Nicholson N S, Panzer-Knodle S G, Haas N F,et al. Assessment of platelet function assays［J］. Am Heart J， 1998, 135(5):S170-178.
［14］ Pinto Slottow T L, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis［J］. Am J Cardiol，2009, 104(4):525-530.
［15］ Agarwal S, Coakley M, Reddy K, et al. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission［J］.Platelet aggregometry,2006, 105(4):676-683.
［16］ Maree A O, Curtin R J, Chubb A, et al． Cyclooxygenase-1 haplotype modulates platelet response to aspirin［J］．J Thromb Haemost, 2005, 3(10) : 2340-2345.
［17］ Hulot J S, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects［J］. Blood,2006, 108(7): 2244-2247.
［18］ Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite［J］. Drug Metab Dispos, 2010,38(1): 92-99.
［19］ Desta Z, Zhao X, Shin J-G, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism［J］.Clin Pharmacokinet, 2002, 41(12): 913-958.
［20］ Mega J L, Close S L, Wiviott S D, et al. Cytochrome p-450 polymorphisms and response to clopidogrel［J］. N Engl J Med,2009, 360(4): 354-362.
［21］ Gilard M, Arnaud B, Legal G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin［J］. J Thromb Haemost, 2006,4(11): 2508-2509.
［22］ Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study［J］. J Am Coll Cardiol, 2009, 54(13): 1149-1153.
［23］ Carney R M, Freedland K E, Eisen S A, et al. Adherence to prophylactic medication regimen in patients with symptomatic versusasymptomatic ischemic heart disease［J］. Behav Med, 1998,24(1):35-39.
［24］ Maree A O, Curtin R J, Dooley M, et al.Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease［J］.J Am Coll Cardiol, 2005,46(7):1258-1263.
［25］ Gurbel P A, Bliden K P, Hayes K M, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting［J］. J Am Coll Cardiol, 2005,45(9):1392-1396.
［26］ Steinhubl S R, Berger P B, Mann J T, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial［J］.JAMA, 2002,288(19):2411-2420.
［27］ Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study［J］. Am Heart J,2009,157(4): 733-739.
［28］ Varenhorst C, James S, Erlinge D,et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease［J］. Eur Heart J,2009,30(14):1744-1752.
［29］ Chu J W, Wong C K, Chambers J, et al. Aspirin resistance determined from a bed-side test in patients suspected to have acute coronary syndrome portends a worse 6 months outcome［J］. QJM,2010,103(6):405-412.
［30］ Crescente M, Dicastelnuovo A, Iacoviello L, et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review［J］. Thromb Haemost, 2008,99(1):14-26.
［31］ Snoep J D, Hovens M M, Eikenboom J C, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis［J］. Am Heart J,2007,154(2):221-231.
［32］ Cao J, Liu L, Fan L, et al. The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease［J］. Aging Male, 2012,15(3):140-147.